HLB (CEO Kim Dong-geon) closed higher on the 29th, while its U.S. subsidiary Immunomic Therapeutics announced that it has initiated the first patient dosing in a U.S. Phase 1 clinical trial for 'ITI-5000,' a vaccine candidate for triple-negative breast cancer.

According to the Korea Exchange, HLB finished trading at 31,250 won, up 850 won (2.80%) from the previous trading day. The previous closing price was 30,400 won. However, no direct causal relationship has been confirmed between the day's stock price increase and the news of Immunomic's clinical progress. Stock prices are influenced by a variety of factors, including market supply and demand, investor sentiment in the biotech sector, and company-specific catalysts.

■ FDA Approval Received in January... 'VITALITI' Study Begins in Earnest

On the 16th, Immunomic administered the first dose to a patient in the Phase 1 clinical trial of ITI-5000 at a local clinical site. Following the receipt of an Investigational New Drug (IND) application approval from the U.S. Food and Drug Administration (FDA) in January, the company proceeded through site activation and patient screening and enrollment processes before entering the dosing stage.

The study, named 'VITALITI,' is a multicenter, open-label, first-in-human clinical trial conducted in patients with Stage 2 to 3 triple-negative breast cancer. It will assess the safety, tolerability, and initial immunological activity of ITI-5000, evaluating both monotherapy and combination with standard adjuvant therapy.

■ UNITE Platform + Self-Amplifying RNA Technology Applied

ITI-5000 is a candidate that applies self-amplifying RNA technology to Immunomic's immunotherapy vaccine platform, 'UNITE.' It is designed to induce a T cell-based anti-cancer immune response by targeting the tumor antigens CT83 and HERV-K, which are expressed in triple-negative breast cancer.

The UNITE platform is a technology that delivers tumor antigens to immune cells to activate CD4-positive T cells, thereby inducing a complex immune response that includes the activation of CD8-positive T cells and antibody production.

Kim Dong-geon, CEO of Immunomic Therapeutics, evaluated the first patient dosing as a milestone marking the full-scale commencement of clinical development, stating the company's intention to confirm safety and immune responses going forward.

■ Future Points to Monitor

Key areas of focus include the safety data emerging from the early clinical stage, the pace of patient enrollment, and the dosing schedule. Since Phase 1 trials are not designed to definitively establish therapeutic efficacy, it is necessary to separately examine subsequent data and the potential for further clinical advancement.

[This article was written with the assistance of AI. This article is informational material for investment reference based on publicly available market data and does not recommend the purchase or sale of any specific stock. Investment decisions and the resulting responsibilities lie solely with the investor.]